IN THIS ISSUE
Legislation & Regulation
Richard Mark Kirkner

JoAnn Volk,
Georgetown University

A bipartisan solution seems unlikely, and Minnesota’s and Oklahoma’s experiences may make states flinch at setting up their own programs.
Medication Management
Thomas Reinke

Robert Rifkin, MD,
US Oncology

Seven biosimilars have crossed the FDA-approval finish line. An abbreviated approval pathway has helped, but some believe the FDA should place more emphasis on relevant phase 3 trials.
Viewpoint
Zachary Hafner
Tomorrow’s Medicine
Thomas Morrow, MD
A partnership that includes two not-for-profit organizations beats out a company formerly led by “pharma bro” Martin Shkreli for the FDA’s OK of benznidazole.